Literature DB >> 28100289

Hepatitis B virus in drug users in France: prevalence and vaccination history, ANRS-Coquelicot Survey 2011-2013.

C Brouard1, J Pillonel1, P Sogni2, A Chollet3, J V Lazarus4, X Pascal3, F Barin5, M Jauffret-Roustide1.   

Abstract

People who use drugs (PWUD) are a key population for hepatitis B virus (HBV) vaccination and screening. We aimed to estimate the seroprevalence of HBs antigen (HBsAg) and self-reported HBV vaccination history in French PWUD attending harm reduction centres using data from the ANRS-Coquelicot multicentre survey conducted in 2011-2013 in 1718 PWUD. Self-fingerprick blood samples were collected on dried blood spots to detect the presence of HBsAg. HBsAg seroprevalence was estimated at 1·4% [95% confidence interval (CI) 0·8-2·5]. It varied between PWUD born in high (7·6%, 95% CI 2·7-19·1), moderate (2·2%, 95% CI 0·8-5·7) and low (0·7%, 95% CI 0·3-1·5) endemic zones. Factors independently associated with HBsAg carriage were being born in a moderate or high endemic zone or reporting precarious housing. Self-reported HBV vaccination history varied from 47·4% in high endemic zones, to 59·3% and 62·6% for moderate and low endemic zones, respectively. Our results suggest that drug use plays a small and substantial role, respectively, in HBsAg carriage in PWUD born in high/moderate and low endemic zones.

Entities:  

Keywords:  Estimating; France; hepatitis B; people who use drugs (PWUD); prevalence of disease; vaccination (immunization)

Year:  2017        PMID: 28100289      PMCID: PMC9507829          DOI: 10.1017/S0950268816003137

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  25 in total

Review 1.  Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis.

Authors:  Geetanjali R Kamath; Dimpy P Shah; Lu-Yu Hwang
Journal:  Vaccine       Date:  2014-03-12       Impact factor: 3.641

2.  Long-term effectiveness of accelerated hepatitis B vaccination schedule in drug users.

Authors:  Dimpy P Shah; Carolyn Z Grimes; Anh T Nguyen; Dejian Lai; Lu-Yu Hwang
Journal:  Am J Public Health       Date:  2015-04-16       Impact factor: 9.308

3.  Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial.

Authors:  Tim Weaver; Nicola Metrebian; Jennifer Hellier; Stephen Pilling; Vikki Charles; Nicholas Little; Dilkushi Poovendran; Luke Mitcheson; Frank Ryan; Owen Bowden-Jones; John Dunn; Anthony Glasper; Emily Finch; John Strang
Journal:  Lancet       Date:  2014-04-08       Impact factor: 79.321

4.  Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales?

Authors:  A Judd; M Hickman; V D Hope; A J Sutton; G V Stimson; M E Ramsay; O N Gill; J V Parry
Journal:  J Viral Hepat       Date:  2007-08       Impact factor: 3.728

Review 5.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

Authors:  Aparna Schweitzer; Johannes Horn; Rafael T Mikolajczyk; Gérard Krause; Jördis J Ott
Journal:  Lancet       Date:  2015-07-28       Impact factor: 79.321

6.  A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia.

Authors:  Libby Topp; Carolyn A Day; Handan Wand; Rachel M Deacon; Ingrid van Beek; Paul S Haber; Marian Shanahan; Craig Rodgers; Lisa Maher
Journal:  Prev Med       Date:  2013-04-29       Impact factor: 4.018

7.  Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors.

Authors:  Christine Meffre; Yann Le Strat; Elisabeth Delarocque-Astagneau; Fréderic Dubois; Denise Antona; Jean-Marie Lemasson; Josiane Warszawski; Josiane Steinmetz; Dominique Coste; Jean-François Meyer; Sandrine Leiser; Jean-Pierre Giordanella; René Gueguen; Jean-Claude Desenclos
Journal:  J Med Virol       Date:  2010-04       Impact factor: 2.327

8.  Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa.

Authors:  Harr Freeya Njai; Yusuke Shimakawa; Bakary Sanneh; Lynne Ferguson; Gibril Ndow; Maimuna Mendy; Amina Sow; Gora Lo; Coumba Toure-Kane; Junko Tanaka; Makie Taal; Umberto D'alessandro; Ramou Njie; Mark Thursz; Maud Lemoine
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

9.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

10.  A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.

Authors:  Marie Jauffret-Roustide; Yann Le Strat; Elisabeth Couturier; Damien Thierry; Marc Rondy; Martine Quaglia; Nicolas Razafandratsima; Julien Emmanuelli; Gaelle Guibert; Francis Barin; Jean-Claude Desenclos
Journal:  BMC Infect Dis       Date:  2009-07-16       Impact factor: 3.090

View more
  3 in total

1.  Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

Authors:  Pierre Gantner; Laurent Cotte; Clotilde Allavena; Firouzé Bani-Sadr; Thomas Huleux; Claudine Duvivier; Marc-Antoine Valantin; Christine Jacomet; Véronique Joly; Antoine Chéret; Pascal Pugliese; Pierre Delobel; André Cabié; David Rey
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

2.  Seroprevalence of Hepatitis B Infection and Associated Risk Factors among Drug Users in Drop-in Centers of Isfahan, Iran.

Authors:  Roya Taleban; Mohammad Moafi; Behrooz Ataei; Majid Yaran; Zary Nokhodian; Nazila Kassaian; Peyman Adibi; Abbasali Javadi
Journal:  Int J Prev Med       Date:  2018-05-16

3.  Acceptability of on-site rapid HIV/HBV/HCV testing and HBV vaccination among three at-risk populations in distinct community-healthcare outreach centres: the ANRS-SHS 154 CUBE study.

Authors:  Ruxandra Calin; Véronique Massari; Gilles Pialoux; Nelly Reydellet; Eve Plenel; Carole Chauvin; Marie Jauffret-Roustide; Nesrine Day; Georges Kreplak; Anaenza Freire Maresca; Nicolas Derche; Sandra Louis; Stanislas Pol; Véronique Doré; Christine Rouzioux; Pierre Chauvin
Journal:  BMC Infect Dis       Date:  2020-11-16       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.